Published on 06/07/2026

Preparing for Inspections: Addressing Poor Data Review Practices in Compliance with Schedule M

Why This Schedule M Topic Matters

In the pharmaceutical industry, the accuracy and credibility of data are non-negotiable. Schedule M, which outlines the Good Manufacturing Practices (GMP) in India, places a strong emphasis on data integrity. Poor data review practices can lead to significant compliance violations, resulting in regulatory scrutiny, product recall, and damage to the organization’s reputation. Failing to conduct effective data reviews undermines the principles of ALCOA Plus—attributable, legible, contemporaneous, original, accurate, and complete—which are fundamental to maintaining data integrity in GMP environments.

Common Compliance Weakness

Many organizations struggle with data review practices due to several common weaknesses:

• Inadequate training on the principles of ALCOA Plus, leading to inconsistencies in data handling.
• Lack of standardized procedures for data review, resulting in varied practices across teams.
• Insufficient cross-verification of data entries, increasing the risk of errors.
• Complacency towards raw data management, where raw data may not be adequately preserved or reviewed before reporting.

Better GMP / Schedule M Approach

To align with Schedule M expectations and improve data review practices, organizations should adopt a cohesive and systematic approach:

1. Develop Comprehensive SOPs: Establish clear Standard Operating Procedures (SOPs) that define the data review process step-by-step, ensuring compliance with Schedule M requirements.
2. Implement Training Programs: Invest in regular training sessions focused on ALCOA Plus principles and the importance of data integrity in achieving compliance.
3. Adequate Data Entry Training: Ensure personnel involved in data capture are trained to understand the significance of accurate data input and its impact on product quality.

Risk-Based Control Considerations

Implementing a risk-based approach to data review practices allows organizations to focus resources effectively. Schedule M requires a risk assessment for manufacturing processes, which extends to data management:

• Identify Critical Data: Determine which datasets are critical to product quality and compliance, and prioritize these for thorough review.
• Assess Risk of Non-Compliance: Evaluate the potential impact of data errors on regulatory compliance and product safety.
• Control Measures: Establish control measures for high-risk data areas, including frequent audits and peer reviews.

Documentation, Training and CAPA Strategy

Documentation is a cornerstone of Schedule M compliance. Establishing a CAPA (Corrective and Preventive Action) strategy for poor data review practices can mitigate risks:

• Document Data Review Processes: Maintain clear records of all data review activities, including who performed review and any corrections made.
• Conduct Root Cause Analysis: For any data discrepancies, perform root cause analysis to identify underlying issues and implement corrective actions.
• Continuous Training Updates: Regularly update training materials based on findings from data reviews and inspection results.

Inspection Relevance

To prepare for CDSCO inspections, organizations must recognize that poor data review practices can result in non-compliance findings. Inspectors often scrutinize the following:

• The thoroughness of data review procedures.
• The presence of documented evidence supporting data accuracy.
• Training records demonstrating staff competency in data handling.

Evidence and Effectiveness Check

It is essential to validate the effectiveness of the implemented practices:

• Internal Audits: Regularly conduct internal audits targeting data handling and reviews to assess compliance with Schedule M.
• Performance Metrics: Establish metrics to gauge the outcome of data review practices and identify areas for improvement.
• Feedback Mechanisms: Encourage feedback from personnel involved in data review to continually enhance processes.

QA Review Questions

To evaluate the robustness of your data review practices, consider the following questions:

• Are all raw data entries reviewed for accuracy and compliance with SOPs?
• Is there a clear record-keeping process for all data review outcomes?
• How frequently are personnel trained on data integrity principles?
• Is there a standardized method for identifying high-risk data areas?
• What corrective actions have been implemented in response to previous data integrity issues?

Practical Example or Sample Wording

Consider the following example of documenting a data review discrepancy:

“On March 15, 2023, during routine data review, a discrepancy was identified in the batch production record of Batch No. 12345, where the yield reported did not match the calculations. The issue was investigated, and a root cause analysis revealed a transcription error. Corrective action included retraining the involved personnel on data entry procedures, and preventive measures involved implementing a dual-entry system for critical data.”

Conclusion

Addressing poor data review practices is vital for maintaining compliance with Schedule M and ensuring data integrity within the pharmaceutical manufacturing environment. By focusing on effective training, robust documentation standards, and a risk-based approach to data management, organizations can strengthen their GMP framework, enhance CDSCO inspection readiness, and safeguard product quality. Continuous improvement and adherence to ALCOA Plus principles will drive the pharmaceutical industry towards operational excellence and regulatory compliance.